Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

Alumis announced positive Phase 3 results for envudeucitinib, a TYK2 inhibitor for moderate-to-severe plaque psoriasis. The drug achieved PASI 90 responses in 68.0% and 62.1% of patients by Week 24, with PASI 100 complete clearance in 41.0% and 39.5%. Quality-of-life improvements and itch relief emerged early, with a favorable safety profile. The company plans to submit an NDA to the FDA in the second half of 2026.

Alumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2.65 million shares. Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are serving as joint book-running managers.

Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.

Alumis Inc. announced it will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib for moderate-to-severe plaque psoriasis on January 6, 2026, at 8:00 a.m. ET. The company will host a conference call and webcast to discuss the results.

Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.

Alumis reported mixed Q2 2025 results, with missed revenue expectations and high operating expenses due to the ACELYRIN merger. The company completed patient enrollment in key clinical trials for envudeucitinib and maintains sufficient funding through 2027.

Alumis Inc. has completed its merger with ACELYRIN, Inc. The merger strengthens Alumis' balance sheet and supports the advancement of its late-stage pipeline of targeted therapies for immune-mediated diseases.

Alumis Inc. and ACELYRIN, INC. announced that Alumis' stockholders voted to approve the pending merger between the two companies. The merger is expected to close in the second quarter of 2025, subject to customary closing conditions.

ACELYRIN stockholders have approved the merger with Alumis, creating a new clinical biopharma company focused on developing transformative therapies for immune-mediated diseases.

ACELYRIN reiterates the benefits of its proposed merger with Alumis, stating that the combination will create a leading clinical-stage immunology company with a diversified portfolio and substantial runway to reach multiple value inflection points. The ACELYRIN board unanimously recommends that stockholders vote in favor of the merger.

Alumis and ACELYRIN have amended their merger agreement, with ACELYRIN stockholders now receiving a higher ownership stake in the combined company. The revised terms aim to maximize value for ACELYRIN stockholders and create a stronger combined entity.